JP2018526423A - 眼科疾患を処置するための化合物および製剤 - Google Patents

眼科疾患を処置するための化合物および製剤 Download PDF

Info

Publication number
JP2018526423A
JP2018526423A JP2018513359A JP2018513359A JP2018526423A JP 2018526423 A JP2018526423 A JP 2018526423A JP 2018513359 A JP2018513359 A JP 2018513359A JP 2018513359 A JP2018513359 A JP 2018513359A JP 2018526423 A JP2018526423 A JP 2018526423A
Authority
JP
Japan
Prior art keywords
optionally substituted
formulation
compound
salt
pharmaceutical formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018513359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526423A5 (enExample
Inventor
レア マクリー，
レア マクリー，
ジェリー ケーグル，
ジェリー ケーグル，
エンジェル パディリャ，
エンジェル パディリャ，
デイビッド ベイカー，
デイビッド ベイカー，
ゲイリー クック，
ゲイリー クック，
ハルン タクルリ，
ハルン タクルリ，
エメット カニンガム，
エメット カニンガム，
Original Assignee
ビューポイント セラピューティクス， インコーポレイテッド
ビューポイント セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビューポイント セラピューティクス， インコーポレイテッド, ビューポイント セラピューティクス， インコーポレイテッド filed Critical ビューポイント セラピューティクス， インコーポレイテッド
Publication of JP2018526423A publication Critical patent/JP2018526423A/ja
Publication of JP2018526423A5 publication Critical patent/JP2018526423A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018513359A 2015-09-08 2016-09-08 眼科疾患を処置するための化合物および製剤 Pending JP2018526423A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562215629P 2015-09-08 2015-09-08
US62/215,629 2015-09-08
US201562269019P 2015-12-17 2015-12-17
US201562269013P 2015-12-17 2015-12-17
US62/269,019 2015-12-17
US62/269,013 2015-12-17
PCT/US2016/050823 WO2017044659A1 (en) 2015-09-08 2016-09-08 Compounds and formulations for treating ophthalmic diseases

Publications (2)

Publication Number Publication Date
JP2018526423A true JP2018526423A (ja) 2018-09-13
JP2018526423A5 JP2018526423A5 (enExample) 2019-10-24

Family

ID=58240060

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018513359A Pending JP2018526423A (ja) 2015-09-08 2016-09-08 眼科疾患を処置するための化合物および製剤

Country Status (8)

Country Link
US (1) US20180250313A1 (enExample)
EP (1) EP3347368A4 (enExample)
JP (1) JP2018526423A (enExample)
CN (1) CN108350021A (enExample)
AU (1) AU2016321254A1 (enExample)
CA (1) CA2998134A1 (enExample)
HK (1) HK1258588A1 (enExample)
WO (1) WO2017044659A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169832A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
HRP20210610T1 (hr) 2013-07-19 2021-05-28 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihove uporabe
PT3035940T (pt) 2013-08-23 2019-01-28 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3885352B1 (en) 2014-10-16 2024-11-27 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
EP4275748A3 (en) 2014-10-16 2024-01-03 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
SMT202100113T1 (it) 2015-01-26 2021-05-07 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
EP3258939B1 (en) 2015-02-20 2022-09-07 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JP6949838B2 (ja) 2015-10-29 2021-10-13 フィルメニッヒ インコーポレイテッドＦｉｒｍｅｎｉｃｈ Ｉｎｃｏｒｐｏｒａｔｅｄ 高甘味度甘味料
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
JOP20190022B1 (ar) 2016-08-23 2023-03-28 Sage Therapeutics Inc ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
JP7285786B2 (ja) 2017-05-03 2023-06-02 フィルメニッヒ インコーポレイテッド 高強度の甘味料の製造方法
CN108794556B (zh) * 2017-05-05 2021-01-29 清华大学 化合物及其在治疗白内障中的应用
MY205909A (en) * 2017-06-08 2024-11-20 Eye Therapies Llc Low-dose brimonidine combinations and uses thereof
WO2019097434A1 (en) * 2017-11-17 2019-05-23 Mahmood Piraee Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders
AU2018372826B2 (en) * 2017-11-22 2023-12-07 Bausch & Lomb Incorporated Ophthalmic viscoelastic compositions
US20200276211A1 (en) * 2017-11-28 2020-09-03 Viewpoint Therapeutics, Inc. Compounds for treating near vision disorders
WO2019191200A1 (en) 2018-03-27 2019-10-03 American Genomics, Llc Method and formulation for producing anesthesia of internal aspect of eye wall by topical application
SG11202012473UA (en) * 2018-06-27 2021-01-28 Cellix Bio Private Ltd Ophthalmic compositions and methods for the treatment of eye disorders
US12286661B2 (en) 2018-11-07 2025-04-29 Firmenich Incorporated Methods for making high intensity sweeteners
JP2022512931A (ja) 2018-11-07 2022-02-07 フィルメニッヒ インコーポレイテッド 高甘味度甘味料の製造方法
AU2020245203A1 (en) * 2019-03-26 2021-11-11 Martin Uram Anesthetic composition and method of anesthetizing the eye
AR119047A1 (es) 2019-05-31 2021-11-17 Sage Therapeutics Inc Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
WO2021113411A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements
WO2021113410A1 (en) * 2019-12-02 2021-06-10 Ampersand Biopharmaceuticals, Inc. Transdermal penetrant formulations for vitamins, minerals and supplements
WO2022023822A1 (en) * 2020-07-30 2022-02-03 Indoco Remedies Limited A stable ophthalmic composition of posaconazole
US20230302032A1 (en) * 2020-08-04 2023-09-28 Harrow Ip Llc Antibacterial compositions and methods for fabricating thereof
US20220112208A1 (en) * 2020-10-08 2022-04-14 King Abdullah University Of Science And Technology Compounds with antiinflammatory activity and methods of use thereof
CN113583950A (zh) * 2021-08-06 2021-11-02 合肥滴碧云生物科技有限公司 一种制备干细胞活性因子的方法及其应用
CN115737654B (zh) * 2021-09-03 2025-11-21 成都瑞沐生物医药科技有限公司 一种滴眼给药预防和/或治疗白内障的眼用制剂
CN119136683A (zh) * 2022-05-02 2024-12-13 祖姆森斯有限公司 耐降解含醛组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513622A (ja) * 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ 白内障及び老眼を阻害する方法
WO2014015024A2 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
WO2014152818A1 (en) * 2013-03-14 2014-09-25 The University Of Massachusetts Methods of inhibiting cataracts and presbyopia
WO2017019808A1 (en) * 2015-07-27 2017-02-02 Catacore, Inc Compositions for the treatment of cataracts

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
FR2663850B1 (fr) * 1990-07-02 1994-01-14 Gird Galderma Composition pharmaceutique ou cosmetique contenant en association un retinouide et un sterol.
US6821774B1 (en) * 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6281774B1 (en) * 1999-09-10 2001-08-28 Sumitomo Special Metals Co., Ltd. Corrosion-resistant permanent magnet and method for producing the same
US20030162758A1 (en) * 2001-12-07 2003-08-28 Schwartz Daniel M. Treatment for age-related macular degeneration (AMD)
US7906147B2 (en) * 2006-10-12 2011-03-15 Nanoprobes, Inc. Functional associative coatings for nanoparticles
US10314917B2 (en) * 2013-03-15 2019-06-11 The Brigham And Women's Hospital, Inc. Targeted polymeric inflammation-resolving nanoparticles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513622A (ja) * 2009-12-14 2013-04-22 ユニバーシティ オブ マサチューセッツ 白内障及び老眼を阻害する方法
WO2014015024A2 (en) * 2012-07-17 2014-01-23 Regents Of The University Of Michigan Non-surgical method of treatment for cataract
WO2014152818A1 (en) * 2013-03-14 2014-09-25 The University Of Massachusetts Methods of inhibiting cataracts and presbyopia
WO2017019808A1 (en) * 2015-07-27 2017-02-02 Catacore, Inc Compositions for the treatment of cataracts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AGING CELL, vol. 2007, Vol.6, No.6, JPN6020028394, pages 807 - 815, ISSN: 0004456550 *

Also Published As

Publication number Publication date
AU2016321254A1 (en) 2018-04-05
CA2998134A1 (en) 2017-03-16
WO2017044659A1 (en) 2017-03-16
CN108350021A (zh) 2018-07-31
US20180250313A1 (en) 2018-09-06
EP3347368A1 (en) 2018-07-18
EP3347368A4 (en) 2019-01-23
HK1258588A1 (zh) 2019-11-15

Similar Documents

Publication Publication Date Title
JP2018526423A (ja) 眼科疾患を処置するための化合物および製剤
KR101918745B1 (ko) 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료
JP5292300B2 (ja) 例えばアルツハイマー病のようなアミロイドまたはアミロイド様タンパク質に関連する疾患の治療のためのｎ−（メチル）−１ｈ−ピラゾール−３−アミン誘導体、ｎ−（メチル）−ピリジン−２−アミン誘導体、およびｎ−（メチル）−トリゾール−２−アミン誘導体
KR20160067103A (ko) 신경 장애를 치료하기 위한 토라세미드 및 바클로펜을 포함하는 조성물
TW200829244A (en) Therapeutic combinations 482
KR20150002681A (ko) App 특이적 bace 억제제(asbi) 및 이의 용도
EP2377860A1 (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
US20250129054A1 (en) Prodrugs of 3,4-methylenedioxy-n-methcathinone and uses thereof
EP3192512B1 (en) Novel pharmaceutical composition for urinary incontinence prevention and/or treatment
KR20150139501A (ko) 안과용 제형
US20230257410A1 (en) Phenothiazine derivatives and uses thereof
US20220340573A1 (en) 1,2,4-oxadiazole derivatives as liver x receptor agonists
US20200276211A1 (en) Compounds for treating near vision disorders
EP2874617B1 (en) Baclofen and acamprosate based therapy of macular degeneration disorders
US11845741B2 (en) Pilocarpine ionic liquids for treatment of glaucoma
CN114007693A (zh) 烟酰胺单核苷酸(nmn)及烟酰胺核苷(nr)的新用途
US11382875B2 (en) Methods and compositions for modulating β-amyloid/α7-nAChR interactions
US20230149357A1 (en) Therapeutic agent for non-motor symptoms associated with parkinson's disease
JP2022502441A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
EP4613272A1 (en) Use of pyridine derivative which is trpv1 antagonist
US20230322672A1 (en) Compounds and formulations for treating ophthalmic diseases
WO2024019661A1 (en) Labdane based compounds and uses thereof
BR112020007787A2 (pt) inibidores ret9 e vegfr2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210302